Karyopharm Therapeutics (KPTI) Finished Goods (2019 - 2025)
Historic Finished Goods for Karyopharm Therapeutics (KPTI) over the last 7 years, with Q4 2025 value amounting to $430000.0.
- Karyopharm Therapeutics' Finished Goods fell 985.32% to $430000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $430000.0, marking a year-over-year decrease of 985.32%. This contributed to the annual value of $430000.0 for FY2025, which is 985.32% down from last year.
- Karyopharm Therapeutics' Finished Goods amounted to $430000.0 in Q4 2025, which was down 985.32% from $433000.0 recorded in Q3 2025.
- In the past 5 years, Karyopharm Therapeutics' Finished Goods registered a high of $991000.0 during Q3 2022, and its lowest value of $114000.0 during Q1 2021.
- Its 5-year average for Finished Goods is $547600.0, with a median of $455000.0 in 2024.
- As far as peak fluctuations go, Karyopharm Therapeutics' Finished Goods skyrocketed by 42405.06% in 2021, and later plummeted by 4401.91% in 2025.
- Quarter analysis of 5 years shows Karyopharm Therapeutics' Finished Goods stood at $414000.0 in 2021, then surged by 135.75% to $976000.0 in 2022, then dropped by 22.34% to $758000.0 in 2023, then tumbled by 37.07% to $477000.0 in 2024, then decreased by 9.85% to $430000.0 in 2025.
- Its Finished Goods stands at $430000.0 for Q4 2025, versus $433000.0 for Q3 2025 and $349000.0 for Q2 2025.